Amgen, Inc.

- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Clinical Trials
1.1k
Trial Phases
6 Phases
Drug Approvals
3
Clinical Trials
Distribution across different clinical trial phases (1008 trials with phase data)• Click on a phase to view related trials
Real World Study to Describe the Effectiveness and Safety of Teprotumumab Among Thyroid Eye Disease Patients
- First Posted Date
- 2025-07-25
- Last Posted Date
- 2025-07-25
- Lead Sponsor
- Amgen
- Target Recruit Count
- 10
- Registration Number
- NCT07085117
- Locations
- 🇨🇳
Boao Vanguard Hospital, Qionghai, Hainan, China
Olpasiran Expanded Access Program
- First Posted Date
- 2025-07-23
- Last Posted Date
- 2025-07-23
- Lead Sponsor
- Amgen
- Registration Number
- NCT07079267
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
- Conditions
- Heart Failure With Preserved Ejection FractionHeart Failure With Mildly Reduced Ejection FractionObesity
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-06-25
- Last Posted Date
- 2025-07-25
- Lead Sponsor
- Amgen
- Target Recruit Count
- 5056
- Registration Number
- NCT07037459
- Locations
- 🇺🇸
SEC Clinical Research, Dothan, Alabama, United States
🇺🇸National Heart Institute, Beverly Hills, California, United States
🇺🇸National Institute of Clinical Research, Huntington Beach, California, United States
A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)
- Conditions
- Extensive Stage Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2025-06-25
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Amgen
- Target Recruit Count
- 380
- Registration Number
- NCT07037758
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Conditions
- Atherosclerotic Cardiovascular DiseaseOverweightObesity
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-06-25
- Last Posted Date
- 2025-07-25
- Lead Sponsor
- Amgen
- Target Recruit Count
- 12800
- Registration Number
- NCT07037433
- Locations
- 🇺🇸
Excel Medical Clinical Trials, Boca Raton, Florida, United States
🇺🇸Velocity Clinical Research - New Smyrna Beach, Edgewater, Florida, United States
🇺🇸Finlay Medical Research, Miami, Florida, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 181
- Next
News
TCG Labs Soleil Raises $400M to Build Single-Asset Biotech Startups for Strategic Partnerships
TCG Labs Soleil, a venture firm collaborating with The Column Group, has raised $400 million to continue launching single-drug biotechnology startups focused on achieving proof-of-concept data for strategic partnerships.
BioVie Strengthens Board with Neuroscience and Finance Veterans as Bezisterim Advances Through Phase 2 Trials
BioVie Inc. appointed Amy S. Chappell, MD, FAAN, and Kameel D. Farag to its Board of Directors to support the company's neurological and liver disease drug development programs.
FDA Appoints Biotech Veteran George Tidmarsh to Lead Drug Regulation Center Amid Agency Restructuring
The FDA has appointed Dr. George Tidmarsh, a former pharmaceutical executive and cancer specialist, to direct the Center for Drug Evaluation and Research, the agency's largest division responsible for reviewing drug safety and effectiveness.
Crescent Biopharma Appoints Jan Pinkas as Chief Scientific Officer to Advance Oncology Pipeline
Crescent Biopharma has appointed Jan Pinkas, Ph.D., as chief scientific officer, bringing over two decades of oncology drug development experience including expertise in antibody-drug conjugates.
Oxford BioTherapeutics and Boehringer Ingelheim Advance Third Oncology Drug Candidate to IND-Enabling Studies
Oxford BioTherapeutics announced that Boehringer Ingelheim has selected a third drug candidate targeting OB33 to advance into IND-enabling studies under their ongoing collaboration.
EPO and UPC Reach Opposite Conclusions on Amgen's PCSK9 Antibody Patent Validity
The European Patent Office (EPO) Opposition Division upheld Amgen's PCSK9 antibody patent EP 3666797, finding it inventive, while the Unified Patent Court (UPC) Central Division revoked the same patent for lacking inventive step.
bluebird bio Strengthens Leadership Team with Three Key Executive Appointments
bluebird bio, a pioneer in gene therapies for severe genetic diseases, has appointed three new executives to strengthen its leadership team as the company focuses on commercial execution.
Sandoz Invests $1.1 Billion in European Biosimilar Manufacturing Hub to Capture $222 Billion Market Opportunity
Sandoz has broken ground on a $440 million biosimilar manufacturing facility in Brnik, Slovenia, bringing total planned investment in the country to over $1.1 billion by 2029.
Avacta Strengthens Leadership Team with Appointment of Chief Medical Officer and Business Development Advisor
Avacta Group plc has appointed David Liebowitz, M.D., Ph.D. as Chief Medical Officer to lead clinical strategy and execution for its targeted cancer therapy pipeline.
Amgen's Bemarituzumab Shows Significant Survival Benefit in Phase 3 Gastric Cancer Trial
Amgen's Phase 3 FORTITUDE-101 trial met its primary endpoint, demonstrating that bemarituzumab plus chemotherapy significantly improved overall survival compared to chemotherapy alone in patients with FGFR2b-positive gastric cancer.